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1. Introduction
1.1. Definition of SCH
SCH is defined when serum TSH concentration is above the statistically upper limit of the
reference range while serum free T4 (FT4) concentration is within its reference range (Biondi &
Cooper, 2008; Surks et al., 2005). Other names for SCH include compensated, early, latent, mild,
minimally symptomatic, preclinical hypothyroidism and euthyroid hyperthyrotropinemia
(Chu & Crapo, 2001). It suggests a compensated early state of primary thyroid failure wherby
an increased level of TSH is required to maintain notmal levels of thyroid hormones. The
reference TSH levels in a normal population aged 12 and older (excluding individuals with
medications or diseases that might influence thyroid function) were assessed at 0.45 to 4.12
mIU/l (2.5th–97.5th percentile) (Hollowell et al., 2002). Although there were age, gender, and
ethnic group differences, they were small and it was therefore not considered necessary to
adjust the reference for these parameters. Additional studies assessing the normal TSH
reference in children have shown broad differences between adult and children that were
dependent on the patient’s age (Elmlinger et al., 2001; Hübner et al., 2002; Kapelari et al.,
2008 ; Soldin et al., 2009; Strich et al., 2012; Zurakowski et al., 1999), indicating that the definition
of SCH is age-dependent. A panel of experts divided patients with SCH into two groups:
patients with mildly increased serum TSH levels (4.5–10 mIU/l) and patients with more
severely increased serum TSH levels (>10 mIU/l) (Surks et al., 2004).
2. Prevalence of SCH
The prevalence of SCH is about 4% to 10% in the adult population (Biondi & Cooper, 2008;
Hollowell et al., 2002; Surks et al., 2004), with a higher prevalence in women and the elderly.
© 2013 Tenenbaum-Rakover; licensee InTech. This is an open access article distributed under the terms of the
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The prevalence of congenital hypothyroidism (CH) has increased in the last two decades from
1 in 4000 births (Grüters et al., 1993) to as high as 1 in 2000 births in the Hispanic population
in the United States (Harris & Pass, 2007). Explanations for the increase in prevalence of CH
in the United States include lower TSH cut-off levels, increasing numbers of preterm or very
low weight babies who can be affected by a transient rise in TSH levels and reflect more benign
or transient cases (Grüters & Krude, 2011) and higher numbers of neonates with Hispanic
background in the tested population. The precise incidence of SCH in children is not well
defined; however, a prevalence of about 1 in 8260 births was found in Europe for transient CH
and SCH (Klett & Schönberg, 1981).
3. Etiology of SCH
The different causes of SCH in children are summarized in Table 1. The most common cause
in children, as well as in adults, is AITD. In the newborn, hyperthyrotropinemia can reflect a
physiological condition, as well as maternal AITD and perinatal exposure to iodine. Loss-of-
function mutations of genes that are involved in thyroid development and thyroid hormone
synthesis may also present as euthyroid hyperthyrotropinemias at birth or later on in life.
Additional etiologies are acquired thyroid infiltration diseases, thyroid injury, and secondary
effects of medication that influences thyroid hormone synthesis or clearance of thyroid
hormones. Mild hyperthyrotropinemia may be a consequence of obesity. Laboratory interfer‐
ence in the assay process is not a rare cause for elevated TSH. Many of these causes result in
overt hypothyroidism with time, or even at presentation.
AITD
Risk factors: family history of AITD-associated
autoimmune disorders (diabetes mellitus type 1, celiac
disease, pernicious anemia, viteligo, atrophic gastritis,
etc.) as part of autoimmune polyglandular syndrome type
1 & 2. In Down syndrome and Turner’s syndrome
Congenital hyperthyrotropinemia
Iodine exposure or endemic iodine deficiency, maternal
AITD, maternal drug treatment like propylthiouraciland
metimazole
Persistent TSH after subacute thyroiditis or painless
thyroiditis
Thyroid injury Partial thyroidectomy, radioactive iodine therapy,external radiotherapy of head and neck, chemotherapy
Drugs
Iodine and iodine-containing medications (amiodorone,
radiographic contrast agents), lithium, interferon α,
sulfonamides
Inadequate replacement therapy of hypothyroidism Inadequate dosage, noncompliance, drug interactions(iron, calcium carbonate, dietary soy), increased T4
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clearance (phenytoin, carbamazepine, phenobarbital),
malabsorption
β-thalassemia major Due to hemosiderosis
After bone marrow transplantation
Thyroid infiltration Amyloidosis, sarcoidosis, hemochromatosis, cystinosis,primary thyroid lymphoma
Obesity
Genetic Loss-of-function mutations in TSHR, GNAS, PAX8, TTF-1,DUOX2
Laboratory interferences Macro-TSH, hetrophylic antibodies, thyroidautoantibodies, RF
Table 1. Causes of SCH in children
3.1. Transient hyperthyrotropinemia in newborns
Hyperthyrotropinemia in newborns is mainly a physiological condition reflecting the TSH
surge which occurs immediately after birth. Additional etiologies for this condition include
iodine deficiency that is common in areas of endemic goiter or secondary to iatrogenic iodine
overload during fetal and postnatal life. Significant exposure to iodine may be caused by
transplacental crossing of iodine to the fetus or secretion of iodine into the breast milk
consumed by the newborn. In addition, the newborn, and especially premature newborns, can
be exposed to iodine overload through contrast medium in imaging studies or to iodine in
topical agents. Rare causes of neonatal hyperthyrotropinemia are transplacental passage of
thyroid-blocking antibodies and antithyroid drugs from mother to fetus in maternal autoim‐
mune diseases. Genetic etiologies include TSH resistance (RTSH), mainly due to mutations in
TSHR. Additional inherited defects include mutations in DUOX2, PAX8, TTF-1 and GNAS1.
Long-term follow-up and laboratory and imaging evaluation are needed to define the specific
etiology and to select the appropriate clinical approach in each case. Sakka et al. (2009) reported
significant elevations in TSH levels in children born after in-vitro fertilization. The authors
hypothesized that this might represent an epigenetic developmental abnormality related to
preimplantation manipulation of the embryo.
3.2. Maturation of thyroid hormone metabolism
Fetal thyroid develops under the influence of increasing TSH levels during the last half of
gestation. Serum TSH increases from low levels at 18 weeks to a peak of 7–10 mU/l at term.
Fetal hypothalamic–pituitary feedback matures during the second trimester (Fiser & Klein,
1981; Fisher & Polk, 1989; Rakover et al., 1999). More recent studies sampling fetal cord blood
have shown measurable TSH levels at as early as 15 weeks gestation which peak in the second
trimester and then plateau at that level until term (Hume et al., 2004; Thorpe-Beeston et al.,
1991). At birth, in response to extrauterine exposure, there is acute release of TSH (TSH surge)
that peaks at a concentration of about 70 mU/l at 30 min and remains elevated for 3 to 5 days
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after birth. The increase in FT4 levels at birth is TSH-dependent. Increased FT4 secretion
continues for 1 to 2 months after birth. Normal pediatric age-dependent references for thyroid
hormones have shown TSH concentrations as high as 9.64 mIU/l in the first months after birth,
suggesting that hyperthyrotropinemia in the first year of life reflects normal phenomena and
does not necessarily require further evaluation or therapy (Hübner et al., 2002).
3.3. Maternal Autoimmune Thyroid Diseases (AITDs)
Transplacental transfer of thyroid-stimulating antibodies (TSAbs) and TSH binding inhibitor
antibodies (TBIAbs) from mother to fetus has been described in the presence of maternal
AITDs. In maternal Graves’ disease, the infant is at risk for congenital hyperthyroidism
(Ogilvy-Stuart et al., 2002), CH and euthyroid hyperthyrotropinemia (Fu et al., 2005). Fu et al.
(2005) reported on 78 mothers with AITDs; about half of their babies had transient hyperthyr‐
otropinemia, seven had overt hypothyroidism and one had hyperthyroidism (Fu et al., 2005).
The severity of the clinical presentation correlated with the levels of maternal autoantibodies.
Congenital hyperthyroidism resulted from maternal transfer of TSAbs. Transient CH or
hyperthyrotropinemia resulted from the mother consuming anti-thyroid drugs such as
metimazole and propylthiouracil, which have a short half life of a few days (Cheron et al.,
1981), and from transplacental transfer of TBIAbs, which are eliminated from the infant’s
serum after a few months in parallel to the elimination of maternal immunoglublulins.
Papendieck et al. (2009) described 28 newborns of mothers with Graves’ disease diagnosed
with neonatal hyperthyroidism (9 newborns), primary hypothyroidism (14) and central
hypothyroidism (5). Spontaneous remission was shown in all of the affected babies between
16 days and 8 months apart from 2 babies who had permanent hypothyroidism. The authors
concluded that infants born to mothers with Graves’ disease should be assessed by a pediatric
endocrinologist to better identify thyroid diseases in the offspring. In maternal Hashimoto's
thyroiditis, the infant is at risk for transient CH or hyperthyrotropinemia due to transplacental
transfer of TBIAbs. To determine the incidence of transient CH due to TRAbs, all dried neonatal
blood specimens from the neonatal screening in North America were screened for TRAbs
(Brown et al., 1996) and only 2% of babies diagnosed with CH were positive for TRAbs,
suggesting that maternal AITD is a rare etiology of CH. The occurrence of transient hypothyr‐
oidism due to maternal Hashimoto's thyroiditis was reported mainly as a case report
(Matsuura et al.,1980; Zakarija et al., 1990; Wada et al., 2000). We described transient CH in
three siblings born to a mother with well-controlled Hashimoto's thyroiditis with extremely
high levels of TBIAbs (Rakover et al., 1990). The baby had high TBIAbs concentrations and as
reflected by sequential serum measurements, these antibodies disappeared after 4 months. In
one sibling, the thyroid gland was absent in a 99mTC scan performed on the first days of life
but repeated scan after the age of 2 years, revealed a gland of normal size and position. Absence
of distal femoral epiphysis at birth was shown. Interestingly, the three siblings had minor
abnormal neurological signs in late childhood such as dyslexia, attention deficit disorder and
coordination disorders. These neurological findings, along with the lack of distal femoral
epiphysis at birth, suggested in-utero fetal hypothyroidism. A less favorable intellectual
outcome was reported in babies with transient CH born to mothers positive for TBIAbs
compared to babies with permanent hypothyroidism of other etiologies, especially if unrec‐
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ognized maternal hypothyroidism was present in utero (Matsuura et al., 1990; Wada et al.,
2000). Our findings as well as other reports raised the dilemma of whether prenatal follow-up,
after umbilical cord blood sampling and intra-amnionic L-T4 injections, if indicated, is required
to prevent late neurological sequels in these cases (Abalovich et al., 2007; De Groot et al.,
2012; Wada et al., 2000). It is recommended that all babies born to mothers with AITDs be
reviewed in the first 3 days of life and a thyroid function test be taken to identify those babies
with transient CH that require L-T4 therapy, or babies with congenital hyperthyroidism
requiring anti-thyroid drugs (Ogilvy-Stuart et al., 2002). The approach for in-utero treatment
of fetal thyroid disease is still a matter of debate (De Groot et al., 2012).
3.4. Exposure to iodine
Abnormal thyroid function due to either iodine deficiency or iodine overload has been
described in prenatal and postnatal periods. In cases of iodine overload, the Wolff-Chaikoff
mechanism blocks the uptake of iodine by the thyroid gland resulting in reduced T4 production
and in turn increased TSH secretion via a negative feedback mechanism. Sava et al. (1984)
showed that newborns from areas of iodine deficiency in Sicily were at higher risk for
hyperthyrotropinemia; the increase in risk was related to the degree of iodine deficiency as
reflected by iodine cord blood measurements. On recall, only two patients were diagnosed
with CH which required L-T4 therapy for as long as 1 year. The authors suggested the need
for maternal iodine prophylaxis therapy in areas of endemic iodine deficiency. Transient
thyroid function abnormalities have also been observed in neonates born to mothers with
excessive iodine intake. Maternal iodine exposure was reported accompanying excess iodine
in the diet (Nishiyama et al., 2004), use of iodine compounds such as povidone iodine in topical
applications, exposure to contrast medium during pregnancy and the use of antiseptic agents
in obstetric departments (Grüters et al., 1983). Prenatally, maternal iodine crosses the placenta
and concentrates in the fetal thyroid gland, whereas postnatally, the newborn is exposed to
iodine through the breast milk (Chanoine et al., 1988; Koga et al., 1995). Premature babies are
particularly susceptible to iodine-induced hypothyroidism due to immaturity of the thyroid–
pituitary negative feedback mechanism and to higher exposure to iodine-containing agents in
intensive care (Delange et al., 1984). Uses of iodine in Cesarean sections and in neonatal
intensive care units are additional causes for newborn iodine overload and therefore it is
recommended to avoid iodine compounds in deliveries and in the neonate intensive care units.
In newborns, exposure to iodine may be attributed to umbilical iodine application as well.
Iodine overload may cause either transient hyperthyroidism with symptoms of tachycardia
and failure to gain weight (Rakover & Adar, 1989) or may present as CH or persistent hyper‐
thyrotropinemia. Nishiyama et al. (2004) described 15 babies with transient CH or persistent
hyperthyrotropinemia born to mothers in Japan who consumed a high iodine diet during their
pregnancies; among them, 12 babies were treated with L-T4. The authors recommended that
food be labeled with their precise amount of iodine to avoid high intake of iodine by pregnant
women. CH and hyperthyrotropinemia in cases of iodine overload or deficiency are transitory;
however, whether transient hypothyroidism or hyperthyrotropinemia can result in permanent
neurological sequels in these cases is not clear, and it is therefore recommended that sort-term
L-T4 therapy be considered on an individual basis.
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4. Genetic etiology of SCH
4.1. TSH Resistance syndrome (RTSH)
RTSH is a condition in which thyroid cells show reduced sensitivity to TSH. This condition is
characterized by elevated serum TSH concentration, a normal or hypoplastic thyroid gland
and normal to very low levels of thyroid hormones (Refetoff, 2003). The diagnosis of RTSH
defect is based on the absence of thyroid antibodies, a lack of goiter, measurable serum
thyroglobulin, and familial occurrence of hyperthyrotropinemia or hypothyroidism. Most of
the cases of RTSH are attributed to mutations in the TSHR but in many cases, no such mutations
were found, suggesting that additional genes are associated with RTSH syndrome (Xie et al.,
1997). The diagnostic work-up of RTSH should exclude PAX8 mutations, which are charac‐
terized by thyroid dysgenesis associated with kidney abnormalities (Grüters et al., 2003; Park
& Chatterjee, 2005) and mutations in GNAS1, which encodes Gsα subunit, causing pseudo‐
hypoparathyroidism (PHP). Another form of RTSH is an autosomal dominantly inherited
disease characterized by euthyroid hyperthyrotropinemia, for which the specific gene has not
yet been identified. This condition has been linked to a locus on chromosome 15q25.3-26.1
(Grasberger et al., 2005). Loss-of-function mutations of DUOX genes are an additional cause
for transient hyperthyrotropinemia.
4.2. TSH Receptor (TSHR)
Loss-of-function mutations in TSHR manifest with a variable clinical spectrum of phenotypes
ranging from severe uncompensated RTSH presenting with CH, or partially compensated
RTSH presenting with SCH or even with normal thyroid function (for review see Tenenbaum-
Rakover, 2012). CH is commonly detected by TSH-based neonatal screening but may missed
by total T4 (TT4)-based screening since, in many cases, TT4 levels are within the normal range
at birth. The degree of CH is variable and depends on the genotype. Severe forms manifest as
overt CH; moderate forms manifest as hypothyroidism identified by neonatal screening
without clinical symptoms of hypothyroidism and mild forms present with hyperthyrotropi‐
nemia and normal thyroid hormone levels. Most of the described cases of CH are detected by
neonatal screening with elevated TSH and normal TT4 levels, but without any clinical symp‐
toms or signs of hypothyroidism (de Roux et al., 1996; Tenenbaum-Rakover et al., 2009).
Nevertheless, L-T4 therapy is initiated in most cases to prevent future consequences of
untreated CH. At the age of 2 to 3 years, when L-T4 is withdrawn, thyroid hormones remain
low in the severe mutations; however in milder mutations, despite extremely elevated TSH
levels, thyroid hormone levels are normal, indicating compensated hypothyroidism (Tenen‐
baum-Rakover et al., 2009). 99mTC scan commonly reveals a normal or hypoplastic gland but
in some cases, an absence of thyroid gland has been demonstrated, suggesting thyroid
agenesis. On the other hand, the presence of detectable thyroglobulin as well as the demon‐
stration of a thyroid gland in the normal position in ultrasonographic imaging exclude thyroid
agenesis and indicate a diagnosis of RTSH. The affected patients who are not identified by
neonatal screening are commonly identified by routine laboratory tests in childhood or even
as adults and are commonly asymptomatic. Most of the described cases are heterozygous for
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TSHR mutations, but biallelic mutations have been reported as well. To date, about 50 different
TSHR mutations have been reported, presenting with a spectrum of phenotypes ranging from
overt CH to mild euthyroid hyperthyrotropinemia. Subjects with euthyroid hyperthyrotropi‐
nemia commonly have stable TSH levels and do not develop overt hypothyroidism with time.
The phenotype correlates with the genotype as the latter is reflected in the severity of hyper‐
thyrotropinemia and the decrease in FT4 levels. Screening for TSHR mutations should be
considered in individuals with apparent nonautoimmune SCH. In view of the variability in
phenotypes and outcomes among individuals with this condition, careful long-term follow-
up is recommended and replacement therapy should be considered on an individual basis
according to thyroid hormone levels in the clinical context. In cases with loss-of-function
mutations in TSHR presenting with CH, early initiation of L-T4 therapy is recommended to
prevent late-effect consequences of hypothyroidism as in other etiologies of CH. However,
withdrawal of L-T4 at the age of 2 to 3 years revealed transient hypothyroidism in some cases,
putting the need for lifelong replacement therapy into question (Alberti et al., 2002; Tenen‐
baum-Rakover et al., 2009). SCH caused by TSHR mutations with mild to moderate loss of
function maintains stable compensated RTSH and may not necessitate thyroid hormone
replacement. Moreover, most patients with RTSH do not present with symptoms of hypo‐
thyroidism or with biochemical parameters of uncompensated hypothyroidism, such as
elevated creatinine phosphokinase (CPK) and liver enzymes and hyperlipidemia (Tenen‐
baum-Rakover et al., 2009). The presence of normal FT4 levels argues against the need for
replacement treatment, especially when inadvertent overtreatment, producing subclinical
hyperthyroidism, can have undesirable effects (Samuels et al., 2008). Contrasting with this
approach, it has been shown that some subjects with RTSH have a slight decrease in FT4 levels
compared to controls, although remaining within the normal range, which may point to a
condition of compensated hypothyroidism in these affected patients. In addition, the possi‐
bility of secondary pituitary enlargement in patients with extreme hyperthyrotropinemia may
support L-T4 replacement therapy. In view of the variability in phenotypes for the different
types of mutations, as well as between individuals with the same genotypes, it is recommended
that careful follow-up and cautious administration of L-T4 be considered based on individual
thyroid hormone levels in the clinical context.
4.3. Pseudohypoparathyroidism (PHP)
Loss-of-function mutations in GNAS1, which encodes Gsα subunit, cause PHP and lead to a
syndrome of resistance to multiple G-coupled receptor hormones. Resistance to parathyroid
hormone (PTH) is the main feature of PHP (Mantovani, 2011; Mantovani et al., 2002). RTSH is
commonly clinically manifested during childhood or adulthood but may present at birth as
CH identified by neonatal screening. In most cases, hypothyroidism is mild and may present
with hyperthyrotropinemia for long durations without any clinical symptoms of hypothyr‐
oidism. 99mTC scan generally demonstrates a hypoplastic gland in a normal position but
absence of a thyroid gland, demonstrated by ultrasonographic imaging, has been reported as
well. SCH is the presenting laboratory finding of PHP in many cases. RTSH is commonly found
in PHP-Ia but is also reported in PHP-Ib. The phenotype of patients with PHP-Ia includes
Albright osteodystrophy presenting with brachydactyly, round face, short stature, central
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obesity, subcutaneous ossifications and variable degree of mental retardation. Clinicians
should be aware of this rare syndrome; in those cases of SCH occurring in obese subjects or
with Albright osteodystrophy phenotype, PHP should be suspected and further hormonal and
molecular evaluations should be considered.
4.4. Dual Oxidase maturation factor (DUOX)
Loss-of-function mutations in DUOX have been reported in children with CH and in transient
hyperthyrotropinemia of the newborn (De Marco et al., 2011; Hoste et al., 2010; Maruo et al.,
2008; Moreno et al., 2002). Hydrogen peroxide (H2O2) is an essential co-substrate for oxidation
of iodine and iodination of thyroglobulin by the thyroid peroxidase (TPO) enzyme. DOUX1
and DOUX2 proteins have a crucial role in H2O2 generation and therefore in thyroid hormone
synthesis. The structure of these proteins includes seven putative transmembrane domains.
Moreno et al. (2002) showed that biallelic mutations of DUOX2 result in organification defect
presenting with permanent CH, whereas monoallelic mutations result in transient CH or
hyperthyrotropinemia (OMIM#606758) (Moreno et al., 2002). In contrast, sequencing of
DUOX2 in Japanese children diagnosed with transient congenital hyperthyrotropinemia
revealed eight novel mutations of the DUOX2 gene, all with biallellic mutations (Maruo et al.,
2008). The authors concluded that even complete inactivation of DUOX2 causes transient, but
not permanent CH, due to the presence of DUOX1, which maintains the supply of H2O2
required for oxidation after the neonatal period. However, late onset of hypothyroidism or
SCH may appear in adulthood during periods of increased requirement for thyroid hormones,
such as in pregnancy (Ohye et al., 2008). The organification defect is characterized by normal
position and location of the thyroid gland in a 99mTC scan, high iodine uptake with partial
positive perchlorate discharge test. Goiter may be present or develop over time (Moreno et al.,
2002; Ohye et al., 2008).
4.5. Thyroid dysgenesis
Three transcription factors have been identified as involved in thyroid development: TTF-1,
TTF-2 and PAX8. The discovery of these transcription factors in a knockout mouse model was
followed by descriptions of the phenotypes in humans. Human mutations in TTF-2 are very
rare and present with CH, cleft palate and spiky hair (OMIM#602617). Patients with TTF-1 and
PAX8 mutations present with either CH or persistent congenital hyperthyrotropinemia; the
former are associated with lung and neurological involvement while the latter are associated
with kidney abnormalities.
4.5.1. TTF-1 mutations
TTF-1, also known as NKX2.1, is a transcription factor involved in thyroid development. Ttf1-
null mice were born dead, lacking a thyroid gland, lung parenchyma and pituitary gland, and
with severe defects in the ventral forebrain. Heterozygous mice presented a euthyroid
phenotype with reduced motor-coordination skills (Park & Chatterjee, 2005). In humans, TTF-1
mutations have been reported in children presenting with SCH, lung involvement presenting
with neonatal respiratory distress and neurological involvement presenting with hypotonia,
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persistent ataxia, dysarthria, microcephaly, choreathetosis and developmental delay (OMIM
#600635). TTF-1 mutations are inherited in an autosomal dominant manner. Patients present
with variable thyroid phenotypes ranging from permanent severe CH to persistent congenital
hyperthyrotropinemia resembling RTSH (Devriendt et al., 1998; Krude et al., 2002; Pohlenz et
al., 2002) with hypoplasticity or agenesis of the thyroid gland or the gland in a normal position
(Krude et al., 2002). TTF-1 mutations may also present with isolated benign hereditary chorea
without thyroid phenotype (Breedveld et al., 2002).
4.5.2. PAX8 mutations
PAX8 is thyroid transcription factor which is a key gene in mammalian embryonic develop‐
ment. Homozygous Pax8-null mice die shortly after weaning and their survival is dependent
on thyroxin replacement therapy. Mutations in the PAX8 gene in humans are characterized
by thyroid dysgenesis associated with kidney abnormalities (Damante 1998; Grüters et al.,
2003; Narumi et al., 2011; Park & Chatterjee, 2005; Vilain et al., 2001) inherited in an autosomal
dominant manner (OMIM#167415). The thyroid gland is hypoplastic (Vilain et al., 2001) or in
an ectopic location. Partial organification defect and partial iodide transport defect have been
reported (Jo et al., 2010). To date, 31 mutations have been described in the PAX8 gene,
presenting as permanent CH or as mild SCH (Narumi et al., 2011; Narumi et al., 2012).
Screening for PAX8 gene mutations in 300 Chinese patients with CH revealed only two subjects
with heterozygous PAX8 mutations, suggesting that PAX8 mutation is a very rare etiology for
CH (Liu et al., 2012).
5. Outcome of neonatal hyperthyrotropinemia
Neonatal hyperthyrotropinemia may be transitory or permanent. Transient congenital
hyperthyrotropinemia has been shown in iodine deficiency or due to iodine overload and in
both of these cases, full recovery is expected within days to a month after the cause has been
removed. In maternal AITD, TRAbs disappear within 4 to 8 months. A less favorable intellec‐
tual outcome was reported in these cases, probably due to in-utero fetal hypothyroidism
(Matsuura et al., 1990; Wada et al., 2000). In cases of persistent congenital hyperthyrotropine‐
mia, minor thyroid abnormalities (Calaciura et al., 2002; Daliva et al., 2000; Leonardi et al.,
2008; Miki et al., 1989; Zung et al., 2010) have been reported in late childhood. Longitudinal
studies assessing the outcome of subjects with neonatal hyperthyrotropinemia have shown a
prevalence of 50% SCH with morphological alterations of the thyroid in early childhood (3
years) (Calaciura et al., 2002), which decreases in follow-up to 30% in late childhood (8 years),
suggesting that persistent hyperthyrotropinemia represents minor congenital thyroid abnor‐
malities (Leonardi et al., 2008). In about 50% of the subjects morphological, immunological or
genetic abnormalities were found. A high rate of thyroid autoantibodies was identified at the
age of 2 to 3 years in about 25% of the subjects (Calaciura et al., 2002); morphological changes
such as enlarged or hypoplastic thyroid gland or its hemiagenesis were shown in 10% of the
cases. Zung et al. (2010) showed that subjects with persistent vs. transient hyperthyrotropine‐
mia had a higher rate of abnormal thyroid imaging and therefore thyroid imaging was
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recommended to distinguish between the persistent and transient forms. Moreover, genetic
analysis revealed heterozygous mutations of TPO and TSHR (Calaciura et al., 2002) in about
5% of the children with SCH following transient neonatal hyperthyrotropinemia. These
findings indicate that hyperthyrotropinemia at birth may represent an inherited thyroid
disease that interferes with thyroid hormone synthesis or thyroid genesis. In contrast to these
studies, Köhler et al. (1996) showed no increase in the risk of thyroid abnormalities and normal
neurological development as well as normal growth in children with hyperthyrotropinemia
at birth; they therefore recommended avoiding longitudinal surveys of these children to
prevent parents' anxiety (Köhler et al., 1996). In summary, neonatal hyperthyrotropinemia
may be persistently associated with either autoimmune disease, inherited thyroid hormone
synthesis defects or morphological changes, and therefore long-term follow-up throughout
childhood is recommended in cases where TSH levels are persistently above the normal range
during the first year of life.
6. Pediatric-age-dependent thyroid hormone reference
The commonly available normal reference range provided by commercial companies for
thyroid hormone levels in routine laboratories is for adults. Using this may result in an
erroneous interpretation of the results of thyroid function in children. Moreover, great
variability exists between the pediatric references published in the literature (Elmlinger et al.,
2001; Hübner et al., 2002; Kapelari et al., 2008; Soldin et al., 2009; Strich et al., 2012; Zurakowski
et al., 1999). The variability in the normal reference range is attributed to different types of
assays, different ethnic and age groups and different sample sizes. Even in the same assay,
different laboratories can provide different normal ranges (Hübner et al., 2002; Kapelari et al.,
2008; Strich et al., 2012). The variability between assays results from the different standards,
antibodies and methods used [two-site immunoassay commonly gives lower results than
radioimmunoassays (RIAs)]. Furthermore, the references established for children in different
age groups make use of different populations; for example, hospitalized children (Hübner et
al., 2002; Kapelari et al., 2008) have lower FT3 concentration due to non-thyroidal illness,
whereas references using routine laboratory samples (Strich et al., 2012) may include samples
from children bearing unidentified thyroid diseases, which may cause an upward bias in the
TSH levels. Despite these limitations, it is still clear that childhood references are very different
from adult references. Strich et al. (2012) showed that in 11,000 samples of children aged 0 to
18 years taken from a routine laboratory database, the upper limit of TSH was 1 mIU/ml above
the provided reference and the lower normal range of FT3 was 0.5 to 2 pmol/l higher than the
reference. Hübner et al. (2002) analyzed thyroid hormone levels in children with the ADVIA®
Centaur TM analyzer. They showed elevated TSH levels in the first year of life with an upper
limit of 9.64 mIU/l, which decreased gradually to 4.9 mIU/l at the age of 18 years. The same
trend was shown with FT4, decreasing from 17.2 to 14.7 pmol/l from 1 to 18 years of age. The
upper limit of FT3 levels showed the same, albeit less pronounced trend, from 8.2 to 6.63 pmol/
l. The authors suggested using continuous-age-dependent reference ranges in children who
show better agreement with biological reality, as these are more reliable than discontinuous
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reference ranges. No significant sex-specific effects on age-adjusted hormone levels were
shown (Hübner et al., 2002; Kapelari et al., 2008). In recent years, there has been some contro‐
versy regarding the normal TSH range for adult populations following the laboratory guide‐
lines from the National Academy of Clinical Biochemistry, indicating that 85% of normal adult
individuals have TSH levels below 2.5 mIU/l. These findings raised a debate over whether
subjects with TSH levels above 2.5 mIU/l have SCH and should be further followed-up by
repeated TSH measurements (Surks et al., 2004; Wartofsky & Dickey, 2005). In summary, age-
dependent references should be used to interpretate thyroid functions in childhood. Hyper‐
thyrotropinemia as high as 6.0 mIU/l (Hübner et al., 2002) with normal thyroid hormone levels
and without clinical symptoms, during the first months of life can be considered within the
upper normal limit for age and therefore not requiring L-T4 therapy. Follow-up with repeated
thyroid function tests is recommended in cases of persistent hyperthyrotropinemia to identify
those infants which may develop late onset overt hypothyroidism.
7. Laboratory pitfalls
In about 0.5 to 5% of patient samples, hyperthyrotropinemia with normal thyroid hormone
levels results from laboratory interference (Ismail et al., 2002). Such interference includes the
presence of heterophilic antibodies, rheumatic factor (RF), autoimmune antithyroid hormone
antibodies and the presence of macro-TSH.
7.1. Heterophilic antibodies
Heterophilic antibodies are antibodies produced against poorly defined antigens of various
animal immunoglobulins. The best known heterophilic antibodies are human antimouse
antibodies (HAMAs). Since immunometric assays use animal antihuman antibodies, the
presence of human antimouse immunoglobulins in an individual's serum could interfere with
the antigen–antibody binding reaction, resulting in falsely high or low hormonal levels. This
interference is very rare in competitive RIAs but well recognized in the two-site sandwich
immunometric assays (Després & Grant, 1988; Halsall et al., 2009; Kaplan & Levinson, 1999).
High false-positive results are commonly reported in the latter, whereas false low levels are
reported in competitive RIAs. High levels of α-fetoprotein, human chorionogonadotropin,
follicle-stimulating hormone, luteinizing hormone, ferritin and tumor markers were described
in TSH measurements secondary to the presence of heterophilic antibodies. Since TSH is
commonly measured in routine evaluations for various medical complaints, elevated TSH
level due to the presence of heterophilic antibodies is not a rare finding. Transient neonatal
hyperthyrotropinemia identified by neonatal screening was reported by Czernichow et al.
(1981), attributed to maternal heterophilic antibodies. The antibodies disappeared from the
circulation within 2 months in the infants and within 4 to 6 months in the mothers (Czernichow
et al., 1981). When heterophilic interference is suspected, further evaluation is indicated. The
first step is to assess the sample using other immunoassays with different antibodies. The
sample should be remeasured after dilution (Ross et al., 2008). Nonlinearity in sample dilution
indicates the presence of laboratory interference. Preincubation of a patient’s sample with
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antiheterophilic tube or mouse serum confirms the diagnosis of heterophilic antibodies. The
clinician should be aware that hyperthyrotropinemia with normal thyroid hormone levels and
without clinical symptoms of hypothyroidism in the newborn or in childhood may be the result
of interference by heterophilic antibodies. The diagnosis of hyperthyrotropinemia due to
heterophilic antibodies cancels the need for further expensive laboratory and imaging
investigations and avoids unnecessary L-T4 therapy.
7.2. Thyroid hormone autoantibodies
Thyroid hormone autoantibodies are present in about 1 to 7% of patients with autoimmune
thyroid diseases, mainly Graves’ disease. Antibodies against thyroglobulin and thyroid
peroxidase are very common in Hashimoto's thyroiditis and Graves’ disease; however,
antibodies against thyroid hormones T3 and T4 are less common and anti-TSH autoantibodies
are even rarer. The presence of thyroid hormone autoantibodies interferes with the assay
procedure, giving higher hormonal levels (Després & Grant, 1998). We had one case of a 16-
year-old girl with Graves’ disease (unpublished data) who presented with severe symptoms
of hypothyroidism, 4 months after 8 mCi of I-131 therapy, with bradycardia and excessive
weight gain. Thyroid function was confusing, with extremely high TSH 136 mIU/dl (0.35–5.5
mIU/dl), extremely high FT4 > 6 (0.88–12.76 ng/ml); low FT3 30 ng/dl (60–180 ng/dl) and
extremely high thyroid stimulating immunoglobulin (TSI) 164 IU/l, anti-TPO > 1000 U/ml and
antithyroglobulin > 3000 U/ml. Measuring FT4 in another assay using different antibodies
revealed low FT4, confirming the clinical diagnosis of hypothyroidism post-radioactive iodine
therapy. The increase in FT4 and TSI concentrations was associated with the autoimmune
overreaction post-I-131 therapy with production of anti-FT4 autoantibodies. This case demon‐
strates the importance of being aware of the existence laboratory interferences for making
correct clinical decisions.
7.3. Macro-TSH
Macro-TSH is a macromolecule that is formed when anti-TSH IgG combines with a TSH
molecule. Due to their large size, these macromolecules are less efficiently cleared from the
circulation by the kidneys, and therefore accumulate in the serum. Since they are nonfunc‐
tioning, they have no clinical significance and therefore may lead to unnecessary therapy. This
condition is commonly described in patients with asymptomatic hyperprolactinemia caused
by macroprolactinemia (Batista et al., 2012). Macro-TSH is rarer than macroprolactinemia with
only about 13 cases described to date (Halsall et al., 2006; Loh et al., 2012; Mendoza, 2009;
Newman et al., 2006; Rix et al., 2011; Sakai et al., 2009). The presence of macro-TSH should be
suspected when the patient is asymptomatic and has elevated TSH level which does not
correlate with additional thyroid function. Nonlinearity when the subject’s serum is diluted
indicates the presence of interfering antibodies. The presence of macro-TSH is proven by
adding polyethylene glycol (PEG) to the patient’s serum. Recovery results less than 50 to 30%
of the pre-PEG results indicate the presence of macro-TSH. The diagnosis of macro-TSH is
confirmed by gel-filtration chromatography but this technique is not routinely available. The
presence of macro-TSH is not part of AITD or autoimmunity. Misdiagnosis of CH identified
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by TSH-based neonatal screening was described in newborns which were later found to have
macro-TSH of maternal origin (Halsall et al., 2006; Newman et al., 2006; Rix et al., 2011). It is
suggested that maternal TSH levels be measured in cases of euthyroid neonates with elevated
serum TSH and normal thyroid hormone. When maternal TSH is persistently elevated, the
presence of macro-TSH should be considered. Further analysis, including recovery with PEG,
is indicated to avoid unnecessary L-T4 treatment. Macro-TSH spontaneously disappears from
the infant's serum at the age of 6 to 8 months in parallel with the elimination of maternal
immunoglobulins.
In summary, clinicians should be aware of false laboratory results attributed to interference in
the immunoassay methods, mainly in evaluating euthyroid hyperthyrotropinemia. In cases in
which there are discrepancies between the clinical presentation and the laboratory results,
antibody interference should be suspected. This may be followed up by further laboratory
evaluation. Accurate diagnosis leads to a better clinical approach and may allow avoiding
unnecessary treatment.
8. Obesity and hyperthyrotropinemia
Obesity in children has become a great medical concern in the last two decades. Thyroid
function tests are part of the diagnostic work-up in children who are overweight or obese.
Moderate elevation in TSH levels in up to 20% of obese children has been demonstrated in
many studies (Eliakim et al., 2006; Grandone et al., 2010; Reinehr, 2011; Reinehr et al., 2006;
Shalitin et al., 2009). Among them, only 7 to 20% showed positive thyroid autoantibodies
(Eliakim et al., 2006; Grandone et al., 2010). It has been speculated that hyperthyrotropinemia
in obesity is a result of elevated leptin which stimulates the hypothalamic–pituitary–thyroid
axis (Reinehr, 2011). The question is whether the elevation in TSH is the cause for or a
consequence of obesity and whether it merits treatment with L-T4. Reiter et al. (2006) did not
find any association between hyperthyrotropinemia and lipid profile, whereas Shalitin et al.
(2009) showed a positive correlation between hyperthyrotropinemia and waist circumference
and triglyceride levels, supporting the need to treat those children. The fact that hyperthyro‐
tropinemia was accompanied by normal FT4 and elevated FT3 levels (Reinehr et al., 2006)
disagrees with the hypothesis of SCH as the cause for obesity in these children. Moreover,
weight loss led to a significant reduction in TSH levels (Eliakim et al., 2006; Grandone et al.,
2010; Reinehr et al., 2006) and L-T4 therapy had no significant influence on body weight or
lipid profile (Eliakim et al., 2006). Most of the studies agree that hyperthyrotropinemia in
obesity is a consequence rather than a cause, and therefore L-T4 therapy is unnecessary in obese
children (Eliakim et al., 2006; Grandone et al., 2010; Reinehr, 2011; Reinehr et al., 2006).
9. Autoimmune Thyroid Disease (AITD) — Hashimoto's thyroiditis
Hashimoto's thyroiditis is characterized by the presence of thyroid autoantibodies [anti-
thyroid peroxidase (TPO) and anti-thyroglobulin (TG)], with or without goiter. This condition
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is characterized by hypoechogenicity of the thyroid gland in ultasonographic imaging and
lymphocytic infiltration of the gland in fine-needle aspiration. The disease commonly appears
in adolescence, with predominantly females affected. Among children with acquired hypo‐
thyroidism, 66% had AITD (Hunter et al., 2000), and about 30% to 50% had a family history of
thyroid diseases (de Vries et al., 2009). The risk of overt hypothyroidism in adults with thyroid
autoantibodies is estimated at 4.3% per year (Vanderpump & Tunbridge, 2002); however, there
are only a few pieces of data on the natural history of Hashimoto's thyroiditis in children
(Gopalakrishnan et al., 2008; Jaruratanasirikul et al., 2001; Moore, 1996; Radetti et al., 2006;
Rallison et al., 1991). Hypoechogenicity of the thyroid gland in ultrasound imaging is a useful
tool for the diagnosis of AITD (Marcocci et al., 1991; Pedersen et al., 2000; Wolgang et al., 2002),
showing higher sensitivity than the thyroid autoantibody tests (100 vs. 63.3%) (Rago et al.,
2001). Marwaha et al. (2008) showed that among children with hypoechogenic appearance of
the gland, 41.4% were positive for FNA, 30.6% were positive for TPO antibodies and 46.8%
showed abnormal thyroid function. They concluded that ultrasound echogenicity is useful
tool for the diagnosis of AITD in children but less sensitive compared to adults (Marwaha et
al., 2008). Moreover, the occurrence of hypoechogenicity has been found to predict evolution
toward hypothyroidism over time in euthyroid subjects (Marcocci et al., 1991; Rago et al.,
2001). Disagreement also exists with regard to the criteria for L-T4 therapy in childhood SCH
(de Vries et al., 2009; Padberg et al., 2001; Radetti et al., 2006; Svensson et al., 2006). Thyroid
function in Hashimoto's thyroiditis in children at presentation is variable. Özen et al. (2011)
found that 36.7% of children were euthyroid, 32.7% had SCH, 16.6% were hypothyroid, 7.9%
had subclinical hyperthyroidism and 5.9% presented with hyperthyroidism (Hashitoxicosis)
(Özen et al., 2011). The main complaint was goiter presenting in 57.85% of patients, most of
which were female (5.7:1, F:M). Similar findings were found by others showing that about 70%
of children are either euthyroid or have SCH (Demirbilek et al., 2007; de Vries et al., 2009;
Skarpa et al., 2011). Moore (1996) showed a benign course of SCH in children and adolescents
with AITD and therefore suggested careful follow–up rather than treating them empirically.
Gopalakrishnan et al. (2008) found that only 12.5% of children with either goiterous euthyroid
or SCH develop overt hypothyroidism within 2 years. In contrast, Jaruratanasirikul et al.
(2001) showed that 50% of subjects with SCH develop overt hypothyroidism within 5 years,
supporting the need for long-term monitoring of thyroid function in patients with thyroid
autoantibodies. de Vries et al. (2009) suggested that L-T4 therapy of euthyroid children with
AITD, if appropriately monitored, is not harmful and may even be beneficial. Further benefit
consisted of reducing thyroid volume in those patients with goiter with or without overt
hypothyroidism (Svensson et al., 2006). Padberg et al. (2001) demonstrated that prophylactic
L-T4 therapy of patients with euthyroid AITD reduces both serological and cellular markers
of autoimmune thyroiditis, indicating that L-T4 therapy might be useful for stopping progres‐
sion of the disease. In contrast, the findings in an adult population that unnecessary long-term
thyroxine therapy or overdose is associated with increase risk for osteopenia, cardiac disease
and other harmful effects (Samuels et al., 2008) argues against regular therapy in children with
AITD-associated SCH.
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10. Natural history
The annual rate of progression of SCH to overt hypothyroidism (elevated TSH with low
thyroid hormones) in an adult population was 4.3% in women with positive thyroid autoan‐
tibodies and only 2% when antibodies were negative (Biondi & Cooper, 2008). Huber et al.
(2002), in a prospective study, found that 28% of women with SCH developed overt hypo‐
thyroidism after 10 years of follow-up. In children, the risk for progression to overt hypothyr‐
oidism is less common and recovery is more frequent. About 25% of subjects with goiterous
thyroiditis had spontaneous remission and 33% developed hypothyroidism over 20 years of
follow-up (Rallison et al., 1991). Radetti et al. (2006) showed, retrospectively, in 160 children
with AITD in an over 5-year follow-up that abnormal thyroid functions occur in 34.3% at
presentation whereas 47.55% had abnormal thyroid function at last visit. However, 10% of
patients with SCH became euthyroid. TSH concentrations showed large fluctuations over time.
The presence of goiter and elevated thyroid autoantibodies at presentation together with an
increase in thyroid autoantibodies and TSH levels in the course of the follow-up were predic‐
tive factors for development of overt hypothyroidism. After 5 years, more that 50% became or
remained euthyroid, and therefore a poor predictive outcome could be shown in individual
patients. The authors suggested that medical therapy should be considered only when
significant deterioration of thyroid function appears (Radetti et al., 2006).
11. Treatment
The dilemma of whether to treat children with SCH is a matter of debate. The risk of developing
overt hypothyroidism in an adult population with SCH was estimated at between 2 to 4.3%
per year, with higher occurrence in patients with positive thyroid autoantibodies and increased
TSH at presentation (Vanderpump & Tunbridge, 2002). In adults, despite extensive studies
and discussion, two different approaches still exist; one expert panel reviewed the available
evidence and concluded that patients with TSH above 10 mIU/l with normal FT4 levels may
be treated, whereas subjects with TSH between 4.5 and 10 mIU/l should be followed-up
without treatment considering the adverse effects of L-T4 on mineral health and heart and the
lack of evidence to support the benefits of the treatment (Surks et al., 2004). On the other hand,
a joint statement of experts from three endocrine societies (American Association of Clinical
Endocrinologists, American Thyroid Association, Endocrine Society) recommended treatment
of subjects with TSH between 4.5 and 10 mIU/l, arguing that lack of evidence does not
necessarily mean lack of benefit (Gharib et al., 2004). Moreover, in view of the recent suggestion
to revise the reference range for adult TSH from 0.3 to 3 mIU/l by the National Health and
Nutrition Examination Survey in United States, indicating that values above this range can be
considered early thyroid failure, additional subjects will be included in the range of TSH within
which thyroxine therapy is justified (Hollowell et al., 2002). In children, most of the subjects
with SCH remain euthyroid over time, and therefore careful follow-up rather than treating
them empirically was suggested (Moore, 1996; Radetti et al., 2006). It is commonly accepted
that children with TSH above 10 mIU/l should be treated even if the FT4 is within a normal
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range while those with TSH between 4.5 and 10 mIU/l with thyroid autoantibodies should be
followed up with repeated thyroid function tests but without treatment (Gopalakrishnan &
Marwaha, 2007). Still, the benefit of L-T4 therapy has been questioned and some studies have
shown no difference in metabolic parameters or neurocognitive function between treated and
untreated subjects (Aijaz et al., 2006; Biondi & Cooper, 2008). On the other hand, it has been
shown that L-T4 therapy of patients with euthyroid AITD reduces both serological and cellular
markers of autoimmune thyroiditis, indicating that L-T4 therapy might be useful in stopping
disease progression (Padberg et al., 2001) and reducing thyroid volume in those patients with
goiter (Svensson et al., 2006). Stable euthyroid hyperthyrotropinemia is a common condition
that usually does not present with clinical symptoms or signs. Furthermore, biochemical
parameters such as increased liver enzyme, hypercholesterolemia or elevated CPK are
negative, indicating a euthyroid state. It is therefore recommended not to treat children
without evidence of clinical hypothyroidism. However, those children with TSH above 10
mIU/l or with a trend toward increasing TSH and decreasing FT4 over time might benefit from
L-T4 therapy. Side effects of L-T4 therapy on the heart with such as resting tachycardia and on
individuals' behavior, such as restlessness and sleep disturbances, should be considered in the
clinical decisions for initiation of therapy. In euthyroid hyperthyrotropinemia caused by
heterozygous loss-of-function mutation of TSHR, TSH levels tend to be stable over the years
and therefore no therapy is indicated (Tenenbaum-Rakover, 2012). In newborns, a different
approach should be taken since delay in therapy may result in permanent intellectual damage.
In the case of TSH levels above 10 mIU/l, early initiation of therapy should be considered, even
if thyroid hormones are within the normal range. In view of the controversy that still exists
around L-T4 therapy in SCH, it is recommended that the decision to initiate therapy be
considered on an individual basis taking into account the benefits and possible side effects. In
pregnant women and in newborns, initiation of therapy should be more urgent, whereas in
other cases, sequential thyroid function tests along with clinical follow-up and further
investigation, including laboratory, imaging and molecular analyses, might be a more
reasonable approach prior to initiation of therapy.
12. Conclusion
The variable causes of SCH in children of different age groups were reviewed. The outcome
of SCH in infancy and during childhood was shown to be dependent on etiology. Long-term
follow-up is recommended since SCH may develop into overt hypothyroidism. Initiation of
L-T4 therapy in children, similar to adults, is still a matter of debate. In newborns, early
initiation of therapy should be considered even if thyroid hormones are within the normal
range to prevent possible late neurological sequels; in older children, on the other hand, it is
recommended that the decision to initiate therapy be considered on an individual basis, taking
into account its benefits and possible side effects.
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